top of page

Science & Pipeline

Proprietary Technology

​We developed the first screening technology allowing drug testing in vitro directly on primary adult brain cells. We incorporate age and sex as biological variables right from the start to develop therapeutics that will benefit those needing it the most. 


There are currently no FDA approved treatments that promote neurological recovery in neurotrauma and neurodegenerative diseases. We are here to change that. Our proprietary screening technology providing a meticulous vetting process is what sets us apart!

Therapeutic Target

Activation of the tropomyosin receptor kinase (Trk) family is essential to healthy neurological function and recovery from injury. Activation of the Trk family decreases with aging and neuropathological conditions, meaning, adults are more susceptible to neurodegenerative diseases and cannot sufficiently recover from neurotraumatic injuries.



NeuroCreis is developing small molecule synthetic activators of Trk to revive our intrinsic abilities to heal from injury and restore our health. Our small molecules are designed to mimic naturally occurring neurotrophins, including brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), with superior pharmacological profiles to effectively enhance our ability to heal from injury and maintain our neurological health.


Our Goals

Promoting Functional Recovery



We are developing therapeutics to improve cognitive abilities, memory function, and  brain health to increase cognitive resilience and promote healthy aging


We aim to improve limb control, coordination, strength, and endurance to support an active lifestyle and give people their freedom back

Overall Health

We focus on the minor details, designing strategies that improve overall life satisfaction by reducing inflammation and fibrosis to enhance organ function and improve cardiometabolic biomarkers

bottom of page